Abilify and Application site erythema - a phase IV clinical study of FDA data

Summary:

Application site erythema is reported as a side effect among people who take Abilify (aripiprazole), especially for people who are male, 10-19 old, have been taking the drug for < 1 month also take Daytrana, and have Attention deficit hyperactivity disorder.

The phase IV clinical study analyzes which people have Application site erythema when taking Abilify. It is created by eHealthMe based on reports of 97,308 people who have side effects when taking Abilify from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,454 Abilify users. Check the latest studies of Abilify.

What is Application site erythema?

Application site erythema (redness of the skin at application site) is found to be associated with 675 drugs and 950 conditions by eHealthMe. Check the latest studies of Application site erythema.

On Jul, 16, 2026

97,308 people reported to have side effects when taking Abilify.
Among them, 37 people (0.04%) have Application site erythema.

Could Abilify cause Application site erythema?

Among these 37 people:

How long have people been on Abilify when they have Application site erythema? *

What is the gender of people who have Application site erythema when taking Abilify? *

female: 40.62 %
male: 59.38 %

What is the age of people who have Application site erythema when taking Abilify? *

What are other drugs people take besides Abilify? *

Daytrana: 23 people, 62.16%
Fentanyl Transdermal System: 5 people, 13.51%
Cymbalta: 5 people, 13.51%
Clonidine: 4 people, 10.81%
Lamictal: 3 people, 8.11%
Ambien: 3 people, 8.11%
Miralax: 2 people, 5.41%
Geodon: 2 people, 5.41%
Gabapentin: 2 people, 5.41%
Sertraline Hydrochloride: 2 people, 5.41%

What are other side effects people have besides Application site erythema? *

Application Site Pruritus (application site severe itching of the skin): 13 people, 35.14%
Application Site Pain: 7 people, 18.92%
Application Site Irritation: 5 people, 13.51%
Drug Ineffective: 4 people, 10.81%
Application Site Rash: 4 people, 10.81%
Drug Effect Increased: 3 people, 8.11%
Abnormal Behavior: 3 people, 8.11%
Application Site Scab (hard coating on the skin formed at application site): 3 people, 8.11%
Application Site Exfoliation (application site removal of the oldest dead skin cells on the skin's outermost surface): 3 people, 8.11%
Application Site Urticaria: 2 people, 5.41%

What are the existing conditions these people have? *

Attention Deficit Hyperactivity Disorder (a chronic condition including attention difficulty, hyperactivity, and impulsiveness): 21 people, 56.76%
Pain: 6 people, 16.22%
Stress And Anxiety: 5 people, 13.51%
High Blood Cholesterol: 3 people, 8.11%
Insomnia (sleeplessness): 3 people, 8.11%
Breakthrough Pain: 3 people, 8.11%
Quit Smoking: 2 people, 5.41%
Anger: 2 people, 5.41%
Sleep Disorder: 2 people, 5.41%
Asthma: 2 people, 5.41%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and have Application site erythema?

- Check whether Application site erythema is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abilify:

Abilify (101,454 reports)

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Application site erythema:

Application site erythema (675 drugs)

Browse all the conditions that are associated with Application site erythema:

Application site erythema (950 conditions)

Related publications that referenced our studies

Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole (the active ingredients of Abilify) and Abilify (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.